Overview

Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
To determine if the use of oral Diindolylmethante (DIM), a marketed cruciferous vegetable based dietary supplement (Bioresponse-DIM), is associated with the regression of cervical dysplasia in otherwise healthy women.
Phase:
Phase 3
Details
Lead Sponsor:
New York Presbyterian Hospital